VanRx_Mike said:The mechanism that matters here is not stomach emptying, it is central.
This answered a question I did not know how to ask. I will report back once I have actually tried it.
Adding the clinical framing, because it changes how the question reads.
NeuroNate said:...but the FDA says semaglutide...
Interesting point. I want to add some regulatory nuance: the FDA labeling reflects the specific clinical trial data submitted for approval. Real-world clinical practice often extends beyond the FDA label based on emerging evidence and clinical judgment.
Example: semaglutide was first approved for diabetes (Ozempic), then obesity (Wegovy). The molecule didn't change — our understanding of its applications expanded. Similarly, semaglutide may evolve as more data accumulates.
Dr.PulmRoch said:Albumin binding above 99% is the whole reason weekly dosing works, and it is also why the trough matters more than the peak.
I read this differently from Dr.PulmRoch, on substance rather than tone. The trial means are being read too generously in this thread. STEP populations were selected, supported, and titrated by protocol, and the real-world curves are consistently a few points worse. That difference is not noise, it is what happens when you remove the study infrastructure.
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsThe figures, for anyone assembling their own picture. If you are comparing against somebody else’s result, check that you are comparing the same measurement taken the same way. Most of the apparent contradictions in these threads dissolve at that step.
Moderator note: reminder that nothing in this thread is medical advice, and that clinical claims need a source.